American International Biotechnology, LLC Sustainability Profile
American International Biotechnology, LLC, commonly referred to as AIB, is a leading player in the biotechnology sector, headquartered in the United States. Founded in 2001, the company has established a strong presence in key operational regions, focusing on innovative solutions in biopharmaceuticals and diagnostics. AIB is renowned for its cutting-edge products and services, including advanced biomanufacturing processes and proprietary diagnostic tools that set it apart in the competitive landscape. The company has achieved significant milestones, including partnerships with major research institutions and contributions to groundbreaking therapies. With a commitment to quality and innovation, American International Biotechnology continues to solidify its market position, recognised for its contributions to the advancement of biotechnology and its impact on healthcare solutions.
DitchCarbon Score
How does American International Biotechnology, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
American International Biotechnology, LLC's score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
American International Biotechnology, LLC's reported carbon emissions
American International Biotechnology, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary, it inherits climate commitments and emissions data from its parent organisation, PathAI, Inc., at a cascade level of four. While there are no documented reduction targets or specific climate pledges from American International Biotechnology, the company is part of a broader corporate family that may engage in sustainability initiatives. However, details regarding specific emissions reductions or commitments are not provided. In the context of the biotechnology industry, companies are increasingly focusing on reducing their carbon footprints and committing to science-based targets. American International Biotechnology's climate strategy may align with these industry trends, but without specific data or commitments, the extent of their initiatives remains unclear.
How Carbon Intensive is American International Biotechnology, LLC's Industry?
How Carbon Intensive is American International Biotechnology, LLC's Location?
American International Biotechnology, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
American International Biotechnology, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
